国际专家共识声明:儿童造血细胞移植与免疫效应细胞治疗后PICU收治及早期重症管理
儿童造血细胞移植联合免疫效应细胞治疗(HCT-IEC)策略与重症监护进步改善了恶性及非恶性疾病患儿的生存预期,但10-35%的HCT-IEC患者仍因疾病相关并发症或治疗相关毒性出现危重症。鉴于PICU中此类患者生存改善,欧洲儿科与新生儿重症监护学会(ESPNIC)、儿科急性肺损伤与脓毒症研究者网络(PALISI)HCT-癌症免疫治疗亚组及欧洲血液与骨髓移植学会(EBMT)儿科疾病工作组共同制定专家共识声明,指导HCT-IEC后患者的PICU收治与早期重症管理。指导委员会起草27条声明,由20名具备HCT与IEC专业知识的专家组成员投票,20条获强同意、7条获弱同意。该共识为重症医师、血液科医师和肿瘤科医师在HCT-IEC后患者PICU收治与重症管理的困难过程中提供指导,并可作为该领域未来研究优先排序的基础。
要点
- 10-35%的HCT-IEC患者因疾病相关并发症或治疗相关毒性出现危重症,是PICU收治与早期重症管理需关注的人群。
- ESPNIC、PALISI网络HCT-癌症免疫治疗亚组与EBMT儿科疾病工作组共同制定该专家共识声明。
- 指导委员会起草27条声明,由20名在HCT与IEC方面具备专长的专家组成员投票。
- 27条声明中20条获强同意、7条获弱同意。
- 该共识旨在指导重症医师、血液科医师和肿瘤科医师对HCT-IEC后患者的PICU收治与重症管理。
适用人群与场景
- 接受造血细胞移植联合免疫效应细胞治疗(HCT-IEC)的儿童患者,涵盖恶性与非恶性疾病。
- 出现疾病相关并发症或治疗相关毒性而需要PICU收治与早期重症管理的HCT-IEC后患儿。
研究设计与关键结果
- 该专家共识声明由ESPNIC、PALISI网络HCT-癌症免疫治疗亚组与EBMT儿科疾病工作组共同制定,用于指导HCT-IEC后患者的PICU收治与早期重症管理。
- 指导委员会起草27条声明,由20名具备HCT与IEC专业知识的专家组成员投票,其中20条获强同意、7条获弱同意。
- 10-35%的HCT-IEC患者因疾病相关并发症或治疗相关毒性出现危重症。
证据类型、等级与局限
- 证据类型:国际专家共识声明。
- 推荐强度:27条声明中20条获强同意、7条获弱同意。
- 局限:原文未报告局限性。
对床旁实践的改变
- 该共识声明可作为重症医师、血液科医师和肿瘤科医师在HCT-IEC后患儿PICU收治与重症管理过程中的指导。
- 该共识声明可作为该领域未来研究优先排序的基础。
指南或共识出处
- 国际专家共识声明:儿童造血细胞移植与免疫效应细胞治疗后PICU收治及早期重症管理(International expert consensus statement on PICU admission and early critical care management for paediatric patients following haematopoietic cell transplant and immune effector cell therapy),发表于Lancet Child Adolesc Health。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Advances in paediatric haematopoietic cell transplantation strategies using immune-effector cells (HCT-IEC) and in intensive care management have improved survival expectations for patients with malignant and non-malignant diseases. However, critical illness still complicates the clinical course for 10-35% of patients undergoing HCT-IEC because of disease-related complications or treatment-related toxicities. Given the improvement in survival for these patients in paediatric intensive care units (PICU), the European Society of Paediatric and Neonatal Intensive Care (ESPNIC), the HCT-Cancer Immunotherapy Subgroup of the Paediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network, and the Paediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation (EBMT) derived expert consensus statements to guide PICU admission and early critical care management of patients following HCT-IEC. 27 statements were drafted by the steering committee and subsequently voted on by 20 expert panel members with expertise in HCT and IEC. 20 statements received strong agreement and seven received weak agreement. This consensus statement serves as a guide for intensivists, haematologists, and oncologists during the challenging process of PICU admission and critical care management of patients who have undergone HCT-IEC and can serve as a basis for prioritising future research in the field.
参考来源
- Di Nardo M, Ghafoor S, Szmit Z, et al. International expert consensus statement on PICU admission and early critical care management for paediatric patients following haematopoietic cell transplant and immune effector cell therapy. Lancet Child Adolesc Health. 2025. PMID: 40379432. doi:10.1016/S2352-4642(25)00091-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。